Assembly Biosciences, Inc. (ASMB) Investor Relations Documents

Assembly Biosciences, Inc. (ASMB) investor relations documents from the company's IR site: 1 presentation, 37 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Assembly Biosciences Corporate Presentation: Assembly Biosciences is advancing therapies for Hepatitis D, Herpesviruses, and Hepatitis B, with key Phase 2 studies in 2026/2027 and a $75M Gilead payment due.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13PresentationAssembly Biosciences Corporate Presentation
2026-08-13Press releasePDF Version
2026-08-13Press releaseAssembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
2026-05-28Press releasePDF Version
2026-05-28Press releaseAssembly Biosciences Announces Upcoming Investor Conference Presentations
2026-05-26Press releasePDF Version
2026-05-26Press releaseAssembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of
2026-05-22Press releasePDF Version
2026-05-22Press releasePDF Version
2026-05-22Press releaseAssembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
2026-05-22Press releaseAssembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
2026-05-13Press releasePDF Version
2026-05-13Press releaseAssembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Cong
2026-05-11Press releasePDF Version
2026-05-11Press releaseAssembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
2026-05-07Press releasePDF Version
2026-05-07Press releaseAssembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
2026-04-09Press releasePDF Version
2026-04-09Press releaseAssembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital H
2026-03-19Press releasePDF Version
2026-03-19Press releaseAssembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
2025-12-22Press releasePDF Version
2025-12-22Press releaseGilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Geni
2025-12-08Press releasePDF Version
DocumentAssembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
2025-11-10Press releasePDF Version
2025-11-07Press releasePDF Version
2025-11-07Press releaseAssembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The
2025-10-14Press releasePDF Version
2025-10-14Press releaseAssembly Biosciences Announces Upcoming Investor Conference Participation
2025-10-10Press releasePDF Version
2025-08-08Press releasePDF Version
2025-08-08Press releasePDF Version
2025-08-08Press releaseAssembly Biosciences Announces Pricing of $175 Million in Equity Financings
DocumentAssembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
2025-08-06Press releasePDF Version
2025-08-06Press releasePDF Version
2025-07-26Press releasePDF Version
2025-07-26Press releaseAssembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and In
2025-06-30Press releasePDF Version

ASMB overview · ASMB earnings · ASMB financials · ASMB KPIs · ASMB ownership · ASMB peers · ASMB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.